John Fuller

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

Helen M. Colhoun, D. J. Betteridge, Paul N. Durrington et al. · The Lancet · 2004 · 3.8K citations

Metabolic Syndrome, Primary Prevention, Diabetes Management +8

Vascular Risk Factors and Diabetic Neuropathy

Solomon Tesfaye, Nish Chaturvedi, Simon E.M Eaton et al. · New England Journal of Medicine · 2005 · 1.3K citations · Full text

Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes

Nish Chaturvedi, Anne-Katrin Sjolie, Judith Stephenson et al. · The Lancet · 1998 · 742 citations

Type 1, Diabetic Retinopathy, Hypertension +7

Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials

Nish Chaturvedi, Massimo Porta, Ronald Klein et al. · The Lancet · 2008 · 449 citations

Type 1, Diabetic Retinopathy, Ocular Disease +7

Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial

Anne Katrin Sjølie, Ronald Klein, Massimo Porta et al. · The Lancet · 2008 · 429 citations

Metabolic Syndrome, Hypertension, Diabetic Retinopathy +9